TM Prepared for your next patient. Review of Selected Changes to the 2012 Immunization Schedules H. Cody Meissner, MD Floating Hospital for Children Tufts University School of Medicine
TM Disclaimers Statements and opinions expressed are those of the authors and not necessarily those of the American Academy of Pediatrics. I have no relevant financial relationships with the manufacturer(s) of any commercial products and/or provider(s) of commercial services discussed in this presentation. I do not intend to discuss an unapproved/investigative use of a commercial product/device in this presentation.
TM Rotavirus Vaccines Two oral vaccines with similar safety and efficacy profiles No change in timing of doses Vaccine contraindicated in 3 groups – Infants with history of allergic reaction after a previous dose – Infants with severe combined immunodeficiency – Infants with history of intussusception
TM Tdap Vaccines Single dose for people 11–18 years who completed recommended DTaP series For children under-immunized with DTaP, single dose of Tdap at 7–10 years Pregnant women after week 20 of gestation Adults ≥65 years if contact with infants <12 months
TM Pneumococcal Vaccine All children 14–59 months who received an age- appropriate series of PCV7 should receive a supplemental dose of PCV13. Invasive pneumococcal disease due to 6 serotypes not in PCV7 is occurring in children who do not receive PCV13. At some CDC sentinel sites, <40% of eligible children are receiving a supplemental dose of PCV13.
TM Influenza Vaccines Guidance on vaccine dosing for children 6 months– 8 years Guidance on vaccination of persons with history of egg allergy Advice regarding risk of febrile seizures when influenza vaccine and PCV13 are administered concurrently
TM Meningococcal Vaccines Routine vaccination at 11, 12 years followed by booster dose at 16 years −If first dose at 13–15 years, give booster dose at 16–18 years −No booster needed if first dose ≥16 years For those with risk factors −2-dose primary series for those <56 years with asplenia, complement deficiency −1 dose for children who travel to or reside in hyperendemic areas or during outbreaks −For children 2–10 years and adults ≥19 years without risk factors, vaccine not recommended
TM Burden of HPV-Associated Cancers Cancers associated with HPV include −Females Cervix, vagina, vulva, anus, oropharynx −Males Penis, anus, oropharynx Approximately 25,000 HPV-associated cancers and 22,000 HPV 16- and 18-associated cancers annually −~15,000 in women (~11,000 cervical cancer) −~7,000 in men
TM Recommendations for Use of Quadrivalent HPV Vaccine Routine 3-dose vaccination for females and males at 11–12 years −0.5 mL administered IM −2nd and 3rd doses 2 and 6 months after 1st dose −Can be administered with other vaccines Catch-up vaccination recommended for females 13–26 years Catch-up vaccination recommended for males 13–21 years −Permissive recommendation for males 22–26 years
TM Thank You Boston Floating Hospital, circa 1920
TM For more information… On this topic and a host of other topics, visit Pediatric Care Online is a convenient electronic resource for immediate expert help with virtually every pediatric clinical information need. Must-have resources are included in a comprehensive reference library and time-saving clinical tools.